135 related articles for article (PubMed ID: 31653561)
1. The role of salvage lymph node dissection in nonmetastatic castration-resistant prostate cancer: A single center experience.
Boeri L; Sharma V; Nehra A; Kwon E; Karnes RJ
Urol Oncol; 2020 Feb; 38(2):38.e9-38.e16. PubMed ID: 31653561
[TBL] [Abstract][Full Text] [Related]
2. Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care: a single-center experience.
Boeri L; Sharma V; Kwon E; Stish BJ; Davis BJ; Karnes RJ
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):514-523. PubMed ID: 33268854
[TBL] [Abstract][Full Text] [Related]
3. Mid-term Outcomes Following Salvage Lymph Node Dissection for Prostate Cancer Nodal Recurrence Status Post-radical Prostatectomy.
Zattoni F; Nehra A; Murphy CR; Rangel L; Mynderse L; Lowe V; Kwon E; Karnes RJ
Eur Urol Focus; 2016 Dec; 2(5):522-531. PubMed ID: 28723518
[TBL] [Abstract][Full Text] [Related]
4. Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought.
Bravi CA; Fossati N; Gandaglia G; Suardi N; Mazzone E; Robesti D; Osmonov D; Juenemann KP; Boeri L; Jeffrey Karnes R; Kretschmer A; Buchner A; Stief C; Hiester A; Nini A; Albers P; Devos G; Joniau S; Van Poppel H; Shariat SF; Heidenreich A; Pfister D; Tilki D; Graefen M; Gill IS; Mottrie A; Karakiewicz PI; Montorsi F; Briganti A
Eur Urol; 2020 Nov; 78(5):661-669. PubMed ID: 32624288
[TBL] [Abstract][Full Text] [Related]
5. Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy.
Bravi CA; Droghetti M; Fossati N; Gandaglia G; Suardi N; Mazzone E; Cucchiara V; Scuderi S; Barletta F; Schiavina R; Osmonov D; Juenemann KP; Boeri L; Karnes RJ; Kretschmer A; Buchner A; Stief C; Hiester A; Nini A; Albers P; Devos G; Joniau S; Van Poppel H; Grubmüller B; Shariat SF; Heidenreich A; Pfister D; Tilki D; Graefen M; Gill IS; Mottrie A; Karakiewicz PI; Montorsi F; Briganti A
Eur Urol Oncol; 2022 Jun; 5(3):285-295. PubMed ID: 34176768
[TBL] [Abstract][Full Text] [Related]
6. The role of salvage extended lymph node dissection in patients with rising PSA and PET/CT scan detected nodal recurrence of prostate cancer.
Porres D; Pfister D; Thissen A; Kuru TH; Zugor V; Buettner R; Knuechel R; Verburg FA; Heidenreich A
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):85-92. PubMed ID: 27824042
[TBL] [Abstract][Full Text] [Related]
7. Robotic salvage lymph node dissection for nodal-only recurrences after radical prostatectomy: Perioperative and early oncological outcomes.
Linxweiler J; Saar M; Al-Kailani Z; Janssen M; Ezziddin S; Stöckle M; Siemer S; Ohlmann CH
Surg Oncol; 2018 Jun; 27(2):138-145. PubMed ID: 29937163
[TBL] [Abstract][Full Text] [Related]
8. Can pelvic node dissection at radical prostatectomy influence the nodal recurrence at salvage lymphadenectomy for prostate cancer?
Sivaraman A; Benfante N; Touijer K; Coleman J; Scardino P; Laudone V; Eastham J
Investig Clin Urol; 2018 Mar; 59(2):83-90. PubMed ID: 29520383
[TBL] [Abstract][Full Text] [Related]
9. Salvage pelvic lymph node dissection in recurrent prostate cancer: surgical and early oncological outcome.
Claeys T; Van Praet C; Lumen N; Ost P; Fonteyne V; De Meerleer G; Lambert B; Delrue L; De Visschere P; Villeirs G; Decaestecker K
Biomed Res Int; 2015; 2015():198543. PubMed ID: 25695051
[TBL] [Abstract][Full Text] [Related]
10. Sentinel Lymph Node Dissection to Select Clinically Node-negative Prostate Cancer Patients for Pelvic Radiation Therapy: Effect on Biochemical Recurrence and Systemic Progression.
Grivas N; Wit E; Pos F; de Jong J; Vegt E; Bex A; Hendricksen K; Horenblas S; KleinJan G; van Rhijn B; van der Poel H
Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):347-354. PubMed ID: 28068243
[TBL] [Abstract][Full Text] [Related]
11. Contemporary role of salvage lymphadenectomy in patients with recurrence following radical prostatectomy.
Abdollah F; Briganti A; Montorsi F; Stenzl A; Stief C; Tombal B; Van Poppel H; Touijer K
Eur Urol; 2015 May; 67(5):839-49. PubMed ID: 24698524
[TBL] [Abstract][Full Text] [Related]
12. Long-term PSA-free survival and castration-free survival with delayed antiandrogen therapy in patients with one versus two or more positive nodes at prostatectomy.
Lodde M; Lacombe L; Naselli A; Puppo P; Mian M; Fradet Y
World J Urol; 2013 Apr; 31(2):293-7. PubMed ID: 22270262
[TBL] [Abstract][Full Text] [Related]
13. PSMA-positive nodal recurrence in prostate cancer : Salvage radiotherapy is superior to salvage lymph node dissection in retrospective analysis.
Schmidt-Hegemann NS; Buchner A; Eze C; Rogowski P; Schaefer C; Ilhan H; Li M; Fendler WP; Bartenstein P; Ganswindt U; Stief C; Belka C; Kretschmer A
Strahlenther Onkol; 2020 Jul; 196(7):637-646. PubMed ID: 32211942
[TBL] [Abstract][Full Text] [Related]
14. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
15. Combining PSA and PET features to select candidates for salvage lymph node dissection in recurrent prostate cancer.
Bravi CA; Heidenreich A; Fossati N; Gandaglia G; Suardi N; Mazzone E; Stabile A; Cucchiara V; Osmonov D; Juenemann KP; Karnes RJ; Kretschmer A; Buchner A; Stief C; Hiester A; Albers P; Devos G; Joniau S; Van Poppel H; Grubmüller B; Shariat S; Tilki D; Graefen M; Gill IS; Mottrie A; Karakiewicz PI; Montorsi F; Briganti A; Pfister D
BJUI Compass; 2023 Jan; 4(1):123-129. PubMed ID: 36569505
[TBL] [Abstract][Full Text] [Related]
16. Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy?
Vidal AC; Howard LE; De Hoedt A; Kane CJ; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Lechpammer S; Flanders SC; Freedland SJ
Cancer; 2019 Feb; 125(3):434-441. PubMed ID: 30427535
[TBL] [Abstract][Full Text] [Related]
17. Oncological outcome of patients treated with spot-specific salvage lymphnode dissection (sLND) for positron-emission tomography (PET)-positive prostate cancer (PCa) relapse.
Hiester A; Nini A; Niegisch G; Arsov C; Hautzel H; Antke C; Schimmöller L; Albers P; Rabenalt R
World J Urol; 2019 Oct; 37(10):2081-2090. PubMed ID: 30643974
[TBL] [Abstract][Full Text] [Related]
18. Extended vs standard lymph node dissection in robot-assisted radical prostatectomy for intermediate- or high-risk prostate cancer: a propensity-score-matching analysis.
Kim KH; Lim SK; Kim HY; Shin TY; Lee JY; Choi YD; Chung BH; Hong SJ; Rha KH
BJU Int; 2013 Jul; 112(2):216-23. PubMed ID: 23356436
[TBL] [Abstract][Full Text] [Related]
19. Rapidly decreasing level of prostate-specific antigen during initial androgen deprivation therapy is a risk factor for early progression to castration-resistant prostate cancer: A retrospective study.
Ji G; Song G; Huang C; He S; Zhou L
Medicine (Baltimore); 2017 Sep; 96(36):e7823. PubMed ID: 28885333
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Peri-operative and Early Oncological Outcomes of Robot-Assisted vs. Open Salvage Lymph Node Dissection in Recurrent Prostate Cancer.
Devos G; Muilwijk T; Raskin Y; Calderon V; Moris L; Van den Broeck T; Berghen C; De Meerleer G; Albersen M; Van Poppel H; Everaerts W; Joniau S
Front Oncol; 2019; 9():781. PubMed ID: 31555579
[No Abstract] [Full Text] [Related]
[Next] [New Search]
